Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
- Go, Se-Il; Lee, Sang-Cheol; Bae, Woo Kyun; Zang, Dae Young; Lee, Hyun Woo; Jang, Joung Soon; Ji, Jun Ho; Kim, Jung Hoon; Park, Sanggon; Sym, Sun Jin; Yang, Yaewon; Jeon, So Yeon; Hwang, In Gyu; Oh, Sung Yong; Kang, Jung Hun
- Issue Date
- ELSEVIER SCI LTD
- Pancreatic neoplasms; Modified FOLFIRINOX; S-1; Second-line chemotherapy; Gemcitabine; Randomised controlled trial
- EUROPEAN JOURNAL OF CANCER, v.157, pp.21 - 30
- Journal Title
- EUROPEAN JOURNAL OF CANCER
- Start Page
- End Page
- Background: The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients with good performance status. Patients and methods: Eighty mPAC patients (age, 19-75 years) refractory to first-line gemcitabine-based chemotherapy were randomly selected to receive mFOLFIRINOX or S-1. mFOLFIRINOX comprised oxaliplatin (65 mg/m(2)), irinotecan (135 mg/m(2)), and leucovorin (400 mg/m(2)) on day 1 and continuous 5-FU infusion (1000 mg/m(2)) over 24 h on days 1-2 every 2 weeks. S-1 comprised body surface area-dependent oral S-1, divided into two doses per day on days 1-28 every 6 weeks. Results: Overall survival was the primary endpoint. The objective response and disease control rates were higher in the mFOLFIRINOX than in the S-1 group (15% versus 2%; p = .04 and 67% versus 37%; p = .007). The median progression-free survival rates were 5.2 and 2.2 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted hazard ratio [HR]: .4; 95% confidence interval [CI]: .2-.6; p < .001). The median overall survival rates were 9.2 and 4.9 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted HR: .4; 95% CI: .2-.7; p = .002). Grade 3-4 adverse events occurred in 56% and 17% of the patients in the mFOLFIRINOX and S-1 groups, respectively (p < .001). Conclusion: Administration of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in increased survival rates than S-1 treatment alone. (C) 2021 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.